Drug Profile
Adalimumab biosimilar - Kidswell Bio
Alternative Names: GBS 005Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Gene Techno Science
- Developer Kidswell Bio
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for research development in Immunological-disorders in Japan (SC, Injection)
- 11 Nov 2021 Early research in Immunological disorders is ongoing in Japan (Kidswell Bio pipeline, November 2021)
- 01 Jul 2021 Gene Techno Science is now called Kidswell Bio